14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SKIN vs MRVI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Maravai LifeSciences Holdings, Inc. (MRVI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas MRVI carries 52.0/100 (HOLD) at $7.40 (N/M Forward P/E, -24.2% operating margin).
Composite vs. Pillar Nuance: While MRVI currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -24.2% operating margin) and revenue trajectory (-2.1% vs. +10.1% YoY).
Competes within the Biotechnology value chain with $2.0B market capitalization and -24.2% operating margin.
OpEx & R&D Reinvestment64.1% of Rev ($137M)
90D Engineering Disclosures0 Published
Investor FAQ SKIN vs MRVI Key Questions & Quantitative Answers
As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Maravai LifeSciences Holdings, Inc. (MRVI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas MRVI carries 52.0/100 (HOLD) at $7.40 (N/M Forward P/E, -24.2% operating margin). Composite vs. Pillar Nuance: While MRVI currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -24.2% operating margin) and revenue trajectory (-2.1% vs. +10.1% YoY).
MRVI leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with MRVI at +10.1% YoY revenue growth and -32.7% YoY earnings growth on $213M TTM revenue (39.9% gross margin, -24.2% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), SKIN cumulative revenue shifted +76.5% while MRVI shifted +35.7%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 64.1% of Rev ($137M) (0 disclosures) for MRVI.
SKIN screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas MRVI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.7x EV/Revenue (-5.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus MRVI (-29.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, MRVI carries 167.3% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.61β · 83% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.